Quince Therapeutics Pursues Reverse Merger Amid Restructuring Effort

Quince Therapeutics ( (QNCX) ) just unveiled an announcement.

On February 9, 2026, Quince Therapeutics engaged LifeSci Capital as exclusive financial adviser to help restructure the company and evaluate strategic alternatives, with an initial focus on pursuing a reverse merger to maximize shareholder value. To fund this process, Quince plans to seek additional capital through potential equity or debt financings, including possible public offerings of common stock, though it warns that such financing may not be available on favorable terms or at all.

Following the failure of its NEAT trial for eDSP and the shutdown of its R&D pipeline, Quince states that shareholders’ only realistic chance of a return now hinges on completing a reverse merger, with liquidation or bankruptcy reorganization likely if no deal is reached. The company also highlights the risk of a Nasdaq delisting due to its share price falling below $1 since January 29, 2026, and cautions that both a delisting and potential acceleration of its EIB loan obligations could further complicate efforts to secure a strategic transaction and leave common shareholders with little or no recovery.

The most recent analyst rating on (QNCX) stock is a Sell with a $0.26 price target. To see the full list of analyst forecasts on Quince Therapeutics stock, see the QNCX Stock Forecast page.

Spark’s Take on QNCX Stock

According to Spark, TipRanks’ AI Analyst, QNCX is a Underperform.

The score is driven primarily by very weak financial performance (no revenue, large losses, sustained cash burn, and a significantly weakened equity position with higher leverage). Technicals also weigh on the score due to a strong downtrend, while valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on QNCX stock, click here.

More about Quince Therapeutics

Quince Therapeutics is a biopharmaceutical company that had focused on developing eDSP, a drug candidate for ataxia-telangiectasia (A-T), but the therapy failed to meet primary and secondary endpoints in its NEAT clinical trial. With no other active product candidates and insufficient resources for further research and development, the company now has no meaningful operating business and is effectively positioned as a shell pursuing corporate transactions rather than drug development.

Average Trading Volume: 3,053,867

Technical Sentiment Signal: Sell

Current Market Cap: $29.38M

See more data about QNCX stock on TipRanks’ Stock Analysis page.